CME

NEEDS STATEMENT
Scientific developments in medical and cosmetic dermatology continue to make it difficult for the busy practitioner to maintain their knowledge base at a level optimal to deliver safe and effective patient care. Advances in our understanding of the pathophysiology of skin diseases coupled with the introduction of new therapeutic agents in the treatment of psoriasis, acne/acne rosacea, vitiligo, melasma, actinic keratoses, pediatric skin disorders, cutaneous viral, bacterial and fungal diseases, and aging skin has widened the physician's knowledge gap regarding diagnostic and therapeutic approaches to these skin disorders. Additionally, most dermatology practices have expanded into the field of cosmetic dermatology where recent advances in laser and non-laser technologies, newer dermal filler agents and expanded applications of Botulinum Toxin A have challenged cosmetic dermatologists to stay current. All of these advances have led to changes in our diagnostic and therapeutic abilities, altered expectations of treatment outcomes and created safety and efficacy issues. Based on this, the need to educate the busy dermatologist is evident, particularly those based in Hawaii, ACMD 2009 was formatted to cover a broad array of topics essential to the daily practice of dermatology. These topics contain needed current information which will be presented in a format in which didactic teaching is balanced by adequate time for discussion and interaction with the presenters.

LEARNING OBJECTIVES
As a result of attending the Advances in Cosmetic and Medical Dermatology Meeting 2009, attendees should be able to:

• Demonstrate increased knowledge regarding the pathogenesis of psoriasis, acne vulgaris, acne rosacea, atopic dermatitis, cutaneous bacterial, fungal and viral infections , actinic keratoses, congenital hemangiomas and nevi, melanoma, melasma, vitiligo; intrinsic and extrinsic aging of the skin. .
  
• Demonstrate increased knowledge regarding mechanisms of action of various drugs and immunomodulatory agents commonly prescribed by dermatologists, including: corticosteroids, newer biologic agents, including TNF inhibitors, T cell targeted therapies, retinoids, methotrexate, cyclosporine; oral and topical acne therapies; .oral and topical antibiotics, antifungals, anti virals; topical skin lightening agents; topical skin repigmenting agents; topical antioxidants and peptides; vaccines; Botulinum Toxin A; dermal filler agents including hyaluronic acid and hydroxyappetite based fillers; lasers, plasma sources and intense pulse light sources.
  
• Describe potential adverse effects that may be related to the use of various drugs and immunomodulatory agents commonly prescribed by dermatologists as well as therapeutic modalities including: corticosteroids, newer biologic agents, including TNF inhibitors, T cell targeted therapies, retinoids, methotrexate, cyclosporine; oral and topical acne therapies; .oral and topical antibiotics, antifungals, anti virals; topical skin lightening agents; topical skin repigmenting agents; topical antioxidants and peptides; vaccines; photodynamic therapy, Botulinum Toxin A; dermal filler agents including hyaluronic acid and hydroxyappetite based fillers; lasers, plasma sources and intense pulse light sources
  
• Define appropriate outcome measures for the optimal follow-up of patients with dermatologic diseases as well as those receiving cosmetic procedures.

Target Audience: dermatologist, physician assistant and nurses and other healthcare practitioners in Dermatology

ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Millennium CME Institute, Inc. and Advances in Cosmetic and Medical Dermatology.  Millennium CME Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.  Millennium CME Institute, Inc. designates this educational activity for a maximum of 38 hours of AMA PRA Category 1 Credit.  Physicians should only claim credit commensurate with the extent of their participation in the activity.

ADA Statement
Special Needs: In accordance with the Americans with Disabilities Act, Advances in Cosmetic and Medical Dermatology seeks to make this conference accessible to all. If you have a disability which might require special accommodations, please contact ACMD at 312-263-1007 or e-mail your needs to: ACMD@htcintl.com.

ACMD Administrative Office
41 E. Lipoa Street, Suite #21
Kihei, Maui, HI 96753
Email: information.services@acmd-derm-hawaii.com